A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)

BACKGROUND: Evidence supports prophylactic use of olanzapine for the treatment of chemotherapy-induced nausea and vomiting (CINV). However, most studies to date have focused on patients with single-day highly emetogenic chemotherapy (HEC). Currently, administration of antiemetic therapies for nausea...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yuanyuan, Yang, Yunpeng, Gao, Fangfang, Hu, Changlu, Zhong, Diansheng, Lu, Miaozhen, Yuan, Zhiping, Zhao, Jianqing, Miao, Jidong, Li, Yan, Zhu, Jie, Wang, Chunbin, Han, Jianjun, Zhao, Yanqiu, Huang, Yan, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874334/
https://www.ncbi.nlm.nih.gov/pubmed/36712888
http://dx.doi.org/10.1016/j.eclinm.2022.101771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874334/
https://www.ncbi.nlm.nih.gov/pubmed/36712888
http://dx.doi.org/10.1016/j.eclinm.2022.101771

Ejemplares similares